Reuben Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-12-2024
- Paid Up Capital ₹ 0.10 M
as on 24-12-2024
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 30.92%
(FY 2020)
- Profit -37.45%
(FY 2020)
- Ebitda -15.39%
(FY 2020)
- Net Worth 9.35%
(FY 2020)
- Total Assets 14.10%
(FY 2020)
About Reuben Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajeev Lochan, Usha Rani, and Anirudh Lochan serve as directors at the Company.
- CIN/LLPIN
U85100DL2007PTC161194
- Company No.
161194
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Reuben Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Lochan  | Director | 28-Mar-2007 | Current |
| Usha Rani | Director | 28-Mar-2007 | Current |
| Anirudh Lochan | Director | 19-Jan-2012 | Current |
Financial Performance of Reuben Pharmaceuticals.
Reuben Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 30.92% increase. The company also saw a substantial fall in profitability, with a 37.45% decrease in profit. The company's net worth moved up by a moderate rise of 9.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Reuben Pharmaceuticals?
Unlock access to Reuben Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Vva Auto Industries Private LimitedActive 10 years 1 monthRajeev Lochan and Usha Rani are mutual person
Ural Health Care Private LimitedActive 22 years 6 monthsRajeev Lochan, Usha Rani and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Reuben Pharmaceuticals?
Unlock and access historical data on people associated with Reuben Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reuben Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reuben Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
